Equities

Stoke Therapeutics Inc

Stoke Therapeutics Inc

Actions
  • Price (USD)14.17
  • Today's Change3.88 / 37.71%
  • Shares traded5.92k
  • 1 Year change+77.57%
  • Beta0.7662
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stoke Therapeutics, Inc. is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with ribonucleic acid-based medicines. Using its Targeted Augmentation of Nuclear Gene Output (TANGO) approach, the Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both the occurrence of seizures and non-seizure comorbidities. Its STK-002 is a ASO in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant (wild-type) copy of the OPA1 gene.

  • Revenue in USD (TTM)8.78m
  • Net income in USD-104.70m
  • Incorporated2014
  • Employees110.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Compass Pathways PLC (ADR)0.00-118.46m610.16m186.00--2.61-----2.39-2.390.003.640.00----0.00-50.06-40.85-54.08-44.48------------0.113-------29.46---12.68--
Cogent Biosciences Inc0.00-192.41m623.40m164.00--2.84-----2.40-2.400.002.990.00----0.00-62.65-49.53-70.07-54.94-------1,684.44----0.00-------37.20--38.48--
Absci Corp5.72m-110.57m624.83m155.00--2.93--109.27-1.20-1.200.06211.890.0212--3.0636,890.32-41.08---46.22-------1,933.65-----93.250.0467---0.5046---5.40------
Olema Pharmaceuticals Inc0.00-96.66m626.25m74.00--2.43-----2.16-2.160.004.620.00----0.00-39.24-30.06-42.54-31.40------------0.00------7.76------
OmniAB Inc34.16m-50.62m631.31m106.00--2.00--18.48-0.4986-0.49860.32922.690.0858--2.00322,301.90-12.71---13.55-------148.16------0.00---42.17---126.65------
Neurogene Inc0.00-36.32m633.14m91.00--3.40-----29.21-29.210.0014.510.00----0.00-21.46-32.70-23.85-34.73------------0.0006------36.90--45.63--
Mineralys Therapeutics Inc0.00-71.90m634.29m28.00--2.18-----1.79-1.790.005.860.00----0.00-39.28---41.38--------------0.00-------141.28------
Sinovac Biotech Ltd420.88m-359.71m639.90m3.56k------1.52-3.63-3.633.9487.080.02922.750.6035118,289.80-5.0955.60-7.7793.17-46.9691.39-174.0067.889.74--0.0174---92.3053.64-98.7333.12102.27--
Phathom Pharmaceuticals Inc682.00k-201.59m646.17m452.00------947.47-3.89-3.890.0133-1.260.0024----1,508.85-69.68-83.26-78.50-93.7775.51---29,558.94-135,982.0010.22-4.911.20-------1.96------
Stoke Therapeutics Inc8.78m-104.70m656.12m110.00--4.08--74.72-2.38-2.380.19963.470.0363--26.9479,827.27-43.23-31.62-49.60-33.92-----1,192.34-1,775.50----0.00---29.22---3.59--11.56--
ACELYRIN Inc-100.00bn-100.00bn657.04m51.00--0.8962----------7.53----------------------------0.00-------54.81------
Mind Medicine (MindMed) Inc0.00-95.73m667.55m57.00--5.00-----2.45-2.450.001.900.00----0.00-65.01---78.34--------------0.1531-------68.55------
Savara Inc0.00-54.70m670.02m37.00--4.77-----0.3424-0.34240.001.020.00----0.00-34.47-36.86-36.36-39.54-------102,587.50----0.158-------43.38--15.91--
Novavax Inc983.71m-545.06m678.77m1.54k------0.69-5.53-5.539.42-5.140.4858.765.18637,527.60-26.88-46.06---269.5765.10---55.41-75.940.6741-38.31-----50.3695.6817.16--108.28--
Data as of Mar 27 2024. Currency figures normalised to Stoke Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

52.14%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 31 Dec 20234.13m9.25%
Morgan Stanley & Co. LLCas of 31 Dec 20233.36m7.52%
Lynx1 Capital Management LPas of 31 Dec 20232.96m6.62%
Redmile Group LLCas of 31 Dec 20232.63m5.88%
Cowen & Co. LLCas of 04 Jan 20242.28m5.10%
Baker Bros. Advisors LPas of 31 Dec 20232.03m4.55%
BlackRock Fund Advisorsas of 31 Dec 20231.82m4.07%
The Vanguard Group, Inc.as of 31 Dec 20231.63m3.64%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 20231.33m2.97%
Granahan Investment Management, LLCas of 31 Dec 20231.14m2.55%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.